Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
National Institutes of Health
Award ceiling
—Award floor
—Posted
Nov 5, 2024Closes
Oct 25, 2027Location eligibility
No specific state restriction found in this listing — check the full opportunity for details.Categories: Education, Health
Eligible applicants: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), County governments, Public and State controlled institutions of higher education, Special district governments, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Independent school districts, Private institutions of higher education, Native American tribal organizations (other than Federally recognized tribal governments), Public housing authorities/Indian housing authorities, For profit organizations other than small businesses, Small businesses, State governments, City or township governments, Native American tribal governments (Federally recognized)
Description
The purpose of this NOFO is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely. These information gaps can result in multiple protocol changes before and after trial start-up, leading to the need for additional time and expenses that may prevent study completion. Further, the suitability and feasibility of new trial designs, which minimize infrastructure and reduce costs may need to be tested in the context of a particular intervention, at-risk group, symptom or venue. Preparatory studies may fill information gaps and address unknowns, improving trial design and knowledge of trial feasibility and thus saving NCI time and money.